Verzenio + fulvestrant
Explore the effectiveness, dosing, and common side effects of Verzenio + fulvestrant.

How effective is Verzenio + fulvestrant?
Verzenio was studied in a clinical trial of 669 women with hormone receptor‑positive (HR+), human epidermal growth factor receptor 2‑negative (HER2–) metastatic breast cancer (MBC), whose disease had progressed after hormone treatment: 446 patients were treated with Verzenio + fulvestrant, and 223 were treated with fulvestrant alone.
Verzenio is helping to raise the bar of what is possible in HR+, HER2− metastatic breast cancer treatment.
Proven to help women live significantly longer
In a clinical study, women taking Verzenio + fulvestrant lived for a median of 46.7 months vs 37.3 months on fulvestrant alone, regardless of menopausal status
More time without disease progression
In the same study, Verzenio + fulvestrant delayed disease progression for a median of 16.4 months vs 9.3 months with fulvestrant alone
- Overall survival (OS) is how long someone lives with cancer, either after being diagnosed or starting treatment. When taking treatment, OS is the days, months, or years that treatment may add to life.
- Progression-free survival (PFS) is the amount of time during and after treatment that the cancer doesn’t get worse. In other words, PFS is how long cancer growth is delayed from the time a treatment is started.
- Progression-free survival (PFS) is the amount of time during and after treatment that the cancer doesn’t get worse. Overall survival (OS) is how long someone lives with cancer after being diagnosed or starting treatment.
SELECT SAFETY INFORMATION
Verzenio may cause serious side effects, including:
Diarrhea is common with Verzenio, may be severe and may cause dehydration or infection. The most common time to develop diarrhea is during the first month of Verzenio treatment. Your doctor may stop your treatment, lower your dose, or tell you to wait to begin your treatment cycle if you have diarrhea.
At the first sign of loose stools, tell your doctor. You may be advised to start taking an antidiarrheal medicine (such as loperamide) and drink more fluids.
Twice as many women saw their tumors shrink
48.1% of patients on Verzenio + fulvestrant saw their tumors shrink vs 21.3% with fulvestrant alone
Complete response: no detectable signs of cancer
In a clinical study, 3.5% of women on Verzenio + fulvestrant had a complete response, or no detectable sign of cancer, vs 0% with fulvestrant alone
Partial response: tumor shrinkage of 30% or more
In a clinical study, 44.7% of women on Verzenio + fulvestrant had a partial response with tumor shrinkage of 30% or more vs 21.3% with fulvestrant alone
SELECT SAFETY INFORMATION
Verzenio may cause serious side effects, including:
Low white blood cell counts (neutropenia) are common with Verzenio and may cause serious infections that can lead to death. Your doctor should check your white blood cell counts before and during treatment. Tell your doctor right away if you have fever or chills.